Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Abt-418. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.97 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.97 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.51 |
| ▸ | CHRM4 known ✓ | P08173 | 3/20 | 0.51 |
| ▸ | CHRM5 known ✓ | P08912 | 3/20 | 0.51 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.51 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.97 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abt-418 SCHEMBL8106821 | 1.00 | CHRNB2 (0.97) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Abt-418 SCHEMBL7586948 | 1.00 | CHRNB2 (0.97) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Abt-418 SCHEMBL8114587 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Abt-418 SCHEMBL2911067 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Abt-418 SCHEMBL194161 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL9260223 | 0.95 | CHRNB2 (0.88) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL9263504 | 0.94 | CHRNB2 (0.91) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Abt-418 SCHEMBL8114179 | 0.91 | CHRNB2 (0.86) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL9270411 | 0.90 | CHRNB2 (0.79) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL14112932 | 0.88 | CHRNB2 (0.81) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | IPS HEART | 2021-02-25 | — | — | US | disclosed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | disclosed |
| EP-1214062-B1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF DRY EYE DISEASE | INSPIRE PHARMACEUTICALS (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20030069272-A1 | Method of enhancing joint lubrication with nicotinic acetylcholine receptor agonists | YERXA BENJAMIN R (US) | 2003-04-10 | — | — | US | disclosed |
| US-6448276-B1 | SUCH AS 1-PYRIDIN-3-YL-4-PYRROLIDIN-1-YL-BUT-1-ENE; INCREASING HYDRATION AND LUBRICATION OF VAGINAL AND CERVICAL TISSUES; NICOTINE, EPIBATIDINE ALKALOIDS AND ANALOGS | INSPIRE PHARMACEUTICALS, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6277855-B1 | STIMULATION OF MUCIN SECRETION IN THE LACRIMAL SYSTEM | INSPIRE PHARMACEUTICALS, INC. | 2001-08-21 | — | — | US | disclosed |
| EP-0717741-B1 | METHOD OF PREPARING ENANTIOMERICALLY-PURE 3-METHYL-5-(1-ALKYL-2(S)-PYRROLIDINYL)ISOXAZOLES | ABBOTT LAB (US) | 2001-05-30 | — | — | EP | disclosed |
| EP-0588917-B1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LAB (US) | 2000-11-08 | — | — | EP | disclosed |
| US-5559242-A | FROM PYROGLUTAMIC ACID, ESTERIFICATION, REACTION WITH DIANION OF ACETONE OXIME, CYCLIZATION, REDUCTION, ALKYLATION | ABBOTT LABORATORIES (US) | 1996-09-24 | — | — | US | disclosed |
| US-5516912-A | FROM PROTECTED 2-OXOPYRROLIDINE | ABBOTT LABORATORIES (US) | 1996-05-14 | — | — | US | disclosed |
| US-5508418-A | FOR MAKING CHOLINERGIC OR ANXIOLYTIC AGENTS | ABBOTT LABORATORIES (US) | 1996-04-16 | — | — | US | disclosed |
| US-5424444-A | Reacting N-alkyl-L-proline ester with salt of dianion of acetone oxime or acetonitrile or other imine anion compounds; cyclization, dehydration after reaction with Grignard reagent and hydroxylamine | ABBOTT LABORATORIES (US) | 1995-06-13 | — | — | US | disclosed |
| US-5409946-A | Antiepileptic agent | ABBOTT LABORATORIES (US) | 1995-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | CHRNB4 2166/4885CHRNA3 1957/4885CHRNA7 2184/4885 |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | EXOSC5, UTRN, EXOSC4 | CHRNB4 903/4885CHRNA3 961/4885CHRNA7 1459/4885 |
| US-20030069272-A1 | Method of enhancing joint lubrication with nicotinic acetylcholine receptor agonists | CHRM3, CHRM2, CHRM4 | CHRNB4 51/4885CHRNA3 13/4885CHRNA7 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.